Nurix therapeutics reports fourth quarter and fiscal year 2023 financial results and provides a corporate update

Nx-5948 received fast track designation from the fda nx-5948 showed positive results in phase 1 clinical trial establishing a robust foundation for advancement in cll licensed to gilead a new development candidate, nx-0479/gs-6791, a targeted protein degrader of irak-4 for rheumatoid arthritis formed strategic collaboration with seagen (now pfizer) to advance a portfolio of degrader-antibody conjugates based on our industry-leading deligase platform achieved $100 million in non-dilutive capital from partners in 2023, including $60 million upfront from seagen and $40 million in success-based milestones and licensing fees from gilead and sanofi maintained strong financial position with cash and investments of $295.3 million san francisco, feb. 15, 2024 (globe newswire) -- nurix therapeutics, inc. (nasdaq: nrix), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today reported financial results for the fiscal quarter and fiscal year ended november 30, 2023, and provided a corporate update. “building on a very successful 2023, marked by impressive clinical data for both nx-5948 and nx-2127, nurix has hit the ground running in 2024, with plans to accelerate enrollment in the nx-5948 leukemia and lymphoma program and enable development in inflammatory diseases,” said arthur t.
NRIX Ratings Summary
NRIX Quant Ranking